Hims & Hers Prepares to Explain an Eighty Percent Profit Decline Nobody Quite Understands Yet

Hims & Hers Health (HIMS) reports first-quarter 2026 earnings after market close on May 11, with Wall Street bracing for a dramatic profitability slowdown despite continued revenue growth. The telehealth platform faces a critical test: can management explain why earnings are expected to plunge 80% year-over-year while the business continues expanding, or will margin pressures prove more structural than investors hoped? With shares trading at $28.27 and analyst sentiment recently improving, the report will determine whether the recent rally can hold or if the profitability concerns trigger a broader reassessment.

Part 1: Earnings Preview

Hims & Hers Health operates a direct-to-consumer telehealth platform offering personalized treatments for conditions including hair loss, sexual wellness, dermatology, and mental health. The San Francisco-based company connects patients with licensed providers through digital consultations and delivers prescription medications and wellness products directly to consumers' homes.

HIMS reports Q1 2026 earnings on May 11 after market close, with analysts expecting EPS of $0.04 on revenue of approximately $616.85 million. The company most recently reported Q4 2025 EPS of $0.07, which crushed estimates of $0.02 by 250%. However, the year-over-year comparison reveals the magnitude of the expected decline: Q1 2025 delivered $0.20 per share, meaning the current consensus implies an 80% earnings collapse from the same quarter last year, even as revenue is projected to grow modestly.

Three key themes define this earnings story:

Margin Compression Mystery: The dramatic earnings decline despite revenue growth points to either significant margin pressure or elevated investment spending. Investors need clarity on whether this represents temporary growth investments, rising customer acquisition costs, or more concerning structural headwinds in the telehealth economics. The wide analyst estimate range—from a $0.04 loss to $0.14 in earnings—reflects deep uncertainty about the company's near-term profitability trajectory.

GLP-1 and Pharmaceutical Partnerships: Recent analyst commentary highlights HIMS positioning itself as a "supply anchor in hormone therapy" and securing fresh endorsements around GLP-1 weight-loss treatments. The company's ability to expand into high-demand therapeutic categories while managing regulatory considerations for compounded medications could provide a growth offset to any margin pressures, making management's commentary on these initiatives critical.

Regulatory and Competitive Dynamics: As a direct-to-consumer pharmaceutical platform, HIMS operates in an evolving regulatory environment for telehealth and compounded medications. Any updates on the competitive landscape, regulatory developments, or shifts in reimbursement dynamics will heavily influence investor confidence in the sustainability of the business model.

Analyst commentary ahead of the release reflects cautious optimism tempered by profitability concerns. While some analysts have maintained buy ratings citing the company's positioning in growing therapeutic categories, the consensus has deteriorated significantly over the past 90 days, with EPS estimates revised down from $0.20 to $0.04—a 78.6% reduction. This steep revision suggests analysts are still grappling with the drivers of margin compression and whether the investment phase will deliver returns.

Part 2: Historical Earnings Performance

HIMS has demonstrated a mixed but generally positive earnings track record over the past four quarters, with three beats and one in-line result. The company's most recent quarter showcased its ability to deliver significant upside surprises: Q4 2025 earnings of $0.07 crushed the $0.02 estimate by 250%, while Q1 2025's $0.20 beat the $0.12 consensus by 66.67%. These substantial beats suggest the company can exceed lowered expectations when operational execution aligns.

However, the pattern reveals increasing volatility in profitability. Q2 2025 delivered a modest 5.56% miss with $0.17 versus $0.18 expected, while Q3 2025 came in exactly at the $0.09 estimate. The wide swings between massive beats and occasional misses reflect the challenges analysts face in modeling a rapidly evolving telehealth business with shifting investment priorities and margin dynamics.

The year-over-year comparison for the upcoming quarter is particularly stark: Q1 2025's $0.20 represents the high-water mark in this dataset, making the expected decline to $0.04 all the more dramatic. This suggests either a fundamental shift in the business economics or a deliberate investment phase that management will need to articulate clearly to maintain investor confidence.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

HIMS typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results drop, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings reveals significant volatility, with the stock averaging an 8.59% absolute move on Day +1 and intraday ranges averaging 15.41% during the first full trading session after results. The most dramatic reaction came after Q1 2025 earnings on May 5, 2025, when the stock surged 18.12% on Day +1 with an intraday range of 29.49%—the quarter that delivered the $0.20 beat. Conversely, Q4 2024 results on February 24, 2025 triggered a 22.32% decline despite a modest beat, suggesting guidance or commentary disappointed.

More recent quarters have shown moderating volatility, with Day +1 moves ranging from 0.32% to 3.60% over the past two reports, though intraday ranges remained elevated at 13-15%. This pattern suggests the market has become somewhat desensitized to earnings beats after multiple quarters of outperformance, but remains highly sensitive to forward guidance and margin commentary. Investors should prepare for potential double-digit percentage swings regardless of whether the company beats or misses the lowered bar.

Part 2.2: Options Market Expected Move

The options market is pricing a 13.59% expected move through the May 15 expiration, implying a range of $24.43 to $32.11. This sits well above the recent Day +1 average move of 8.59% but below the 15.41% average intraday range, suggesting options traders are pricing in elevated volatility consistent with the stock's historical earnings behavior. The elevated implied volatility of 143.33% reflects significant uncertainty around both the magnitude and direction of the post-earnings move.

Part 3: What Analysts Are Saying

Analyst sentiment on HIMS has improved recently, though the overall stance remains cautious. The consensus rating stands at 3.44 (between Hold and Buy), with 3 Strong Buys, 1 Moderate Buy, and 12 Holds among the 16 analysts covering the stock. Notably, there are zero sell ratings, suggesting analysts see limited downside risk despite profitability concerns. The average price target of $27.25 sits essentially at the current price of $28.27, implying 3.6% downside, though the range spans from a low of $18.00 to a high of $40.00—reflecting deep disagreement about the company's valuation.

The sentiment improvement over the past month is notable: the consensus rating has strengthened from 3.33 to 3.44, and Strong Buy ratings increased from 2 to 3. This suggests some analysts are gaining confidence in the company's long-term positioning despite the near-term earnings headwinds. The wide price target range and the concentration of Hold ratings indicate most analysts are taking a wait-and-see approach, likely wanting more clarity on margin trends and the sustainability of growth investments before committing to more bullish stances.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Sell signal at 8%, representing a significant improvement from 24% Sell last week and 80% Sell last month. This dramatic shift suggests technical momentum has stabilized after a period of weakness, though the signal remains in bearish territory heading into earnings.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum has recovered from recent lows
• Medium-term (50% Sell): Moderate sell signal suggests consolidation or weakness in the intermediate timeframe
• Long-term (50% Sell): Moderate sell signal reflects ongoing pressure in the longer-term trend

Trend Characteristics: The Weak strength combined with a Weakening direction indicates the stock remains in a fragile technical environment despite recent stabilization, suggesting limited technical support heading into the earnings catalyst.

The stock trades at $28.27, positioned above its 5-day ($26.88), 10-day ($27.26), 20-day ($27.19), 50-day ($23.19), and 100-day ($25.39) moving averages, but remains below the critical 200-day moving average at $36.71.

The technical setup presents a mixed picture: while the stock has reclaimed all short- and intermediate-term moving averages, the 23% gap below the 200-day average represents significant overhead resistance and reflects the stock's decline from higher levels earlier in the cycle. The recent stabilization in the Barchart Opinion signal suggests the worst of the technical damage may be behind the stock, but the weak trend characteristics and bearish medium- and long-term signals indicate limited technical cushion if earnings disappoint. The proximity to the $27.25 average analyst price target suggests the stock is fairly valued at current levels, leaving the post-earnings direction heavily dependent on management's ability to articulate a credible path back to the profitability levels seen a year ago.